
USFDA16 Nov 2026, 08:37 am
Biocon Gets US FDA Approval for Oncology Drug Pebrilzo
AI Summary
Biocon Limited announced that the U.S. Food and Drug Administration (FDA) has approved Pebrilzo™ (pertuzumab-qcay), a biosimilar to Perjeta® (pertuzumab). This monoclonal antibody is used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer cells. The approval strengthens Biocon's oncology portfolio, making Pebrilzo its fifth oncology biosimilar approved in the U.S. The company has a global settlement and license agreement with Genentech for the earliest licensed launch in the U.S. in Q3 2028. Biocon's existing oncology therapies include Ogivri®, Jobevne®, Fulphila®, and Aukelso®.
Key Highlights
- US FDA approves Biocon's biosimilar Pebrilzo for HER2-positive breast cancer.
- Pebrilzo is Biocon's fifth oncology biosimilar approved in the United States.
- Strengthens Biocon's oncology portfolio and commitment to affordable biologics.
- Anticipated U.S. launch in Q3 2028 following Genentech agreement.
Price Impact
More from BIOCON